TELA Bio (TELA) Net Cash Flow Growth (1y) (2019 - 2026)
TELA Bio (TELA) Net Cash Flow Growth (1y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.36 Bn | 175.06 Bn | 6.27 Bn | -53.07% |
| 2 | Stryker | 128.86 Bn | 125.99 Bn | 3.81 Bn | 17.60% |
| 3 | Medtronic | 108.02 Bn | 98.80 Bn | 6.41 Bn | 10.50% |
| 4 | Boston Scientific | 68.21 Bn | 66.76 Bn | 3.61 Bn | -283.58% |
| 5 | Edwards Lifesciences | 48.19 Bn | 44.52 Bn | 1.29 Bn | -564.44% |
| 6 | Dexcom | 28.30 Bn | 27.18 Bn | 750.30 Mn | -31.84% |
| 7 | GE HealthCare Technologies | 28.02 Bn | 25.74 Bn | 1.98 Bn | -394.13% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 24.11 Bn | 20.99 Bn | 2.07 Bn | 76.43% |
| 10 | TELA Bio | 38.25 Mn | -1.29 Mn | 12.52 Mn | -16.23% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.23% |
| Dec 31, 2025 | -39.84% |
| Sep 30, 2025 | 40.24% |
| Jun 30, 2025 | 27.56% |
| Mar 31, 2025 | -0.74% |
| Dec 31, 2024 | 413.55% |
| Sep 30, 2024 | -28.10% |
| Jun 30, 2024 | -130.40% |
| Mar 31, 2024 | 19.22% |
| Dec 31, 2023 | 8.38% |
| Sep 30, 2023 | -126.40% |
| Jun 30, 2023 | 767.96% |
| Mar 31, 2023 | -9.27% |
| Dec 31, 2022 | -26.23% |
| Sep 30, 2022 | 499.73% |
| Jun 30, 2022 | 5.42% |
| Mar 31, 2022 | -27.31% |
| Dec 31, 2021 | -36.74% |
| Sep 30, 2021 | -66.47% |
| Jun 30, 2021 | -112.57% |